SAN DIEGO--(BUSINESS WIRE)--India’s leading biopharmaceutical company, Intas Biopharmaceuticals Ltd. (IBPL, www.intasbiopharma.co.in), has acquired US-based biotechnology corporation, Biologics Process Development Incorporated (BPD Inc., www.biologicspd.com), based in Poway, California. With the acquisition process underway, both Intas Biopharma and BPD Inc. are actively pursuing plans to work closely toward fulfillment of common business objectives in the area of biologics Contract Research and Manufacturing Services (CRAMS).
This development will facilitate and assist Intas Biopharma’s foray into the US market especially to expand its CRAMS business. With mutual understanding and agreement between the two companies, Dr. Scott M. Brown, Founder, President and Chief Scientific Officer of BPD, Inc., will continue as President and Chief Scientific Officer.
Expressing his view on the development, Dr. Brown said, “We are pleased to become associates with Intas Biopharmaceuticals, a leader in the area of biologics research and manufacturing in India. Jointly we complement each other on the technology front, and we at BPD Inc. are looking forward to working with Intas and exploring new technology frontiers.”
Intas Biopharma’s venture into the CRAMS business has opened up new vistas for R&D in the area of biopharmaceuticals and biosimilars. According to Dr. Dhananjay Patankar, CTO of Intas Biopharmaceuticals Ltd., “IBPL has taken up the CRAMS opportunity in the biotechnology space as a focus area with tremendous potential and is preparing to scale up its facilities. IBPL offers a unique business model for offshore clients, providing competitive advantages in terms of developing new biotech products, technology transfer and contract manufacturing in a seamless manner and at committed costs, quality, and time.”
Contact:
Biologics Process Development, Inc. Dr. Scott M. Brown, 858-486-9850 smbrown@biologicspd.com or Intas Biopharmaceuticals Ltd. Mr. Mani Iyer, +91 2717 660 100 mani.iyer@intasbiopharma.co.in
Source: Biologics Process Development, Inc. and Intas Biopharmaceuticals Ltd.
